AUAUniversity American Urological Association

AUA2024: AUA Advanced Prostate Cancer Guidelines

CME Available: https://auau.auanet.org/node/41027

At the conclusion of this activity, participants will be able to:
1. Identify appropriate use of genetic testing and genetic counseling.
2. Identify appropriate use of somatic testing and treatments related to specific genetic alterations.
3. Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy. Early treatment intensification will be discussed in metastatic hormone-sensitive prostate cancer.
4. Identify the treatments for nonmetastatic CRPC and oncologic outcomes based on AUA/SUO (Society of Urologic Oncology) Guidelines.
5. Cancel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO Guidelines.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Live from AUA2024: Highlights in Bladder Cancer

CME Available: https://auau.auanet.org/node/41085

At the conclusion of this activity, participants will be able to:
1. Discuss the newly released amendment to the AUA/SUO Guideline on Non-Muscle Invasive Bladder Cancer.
2. Describe recent developments in the management of non-muscle invasive bladder cancer.
3. Review current management approaches for non-metastatic muscle-invasive bladder cancer.
4. Identify novel therapies and their mechanism of action in the management of advanced bladder cancer.

ACKNOWLEDGEMENT
This educational activity is supported by independent educational grant from:
Merck & Co., Inc.

AUA2024: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management

CME Available: https://auau.auanet.org/node/41040

At the conclusion of this activity, participants will be able to:
1. Identify clinically available data that can help assess risk of UTUC disease.
2. Verbalize the important role of kidney function before and after nephroureterectomy in the management of UTUC, and calculate the estimated new baseline glomerular filtration rate.
3. Compare the clinical trial data on intravesical, neoadjuvant and adjuvant chemotherapy.
4. Recognize the possibility of an undiagnosed inheritable syndrome in patients with UTUC, ask about history of nongenitourinary cancers, and identify the clinical methods for screening and diagnosis of inheritable syndromes.
5. Recognize the importance of preoperative chemotherapy and response-based surgical management for locoregional nodal recurrence after nephroureterectomy.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Merck & Co., Inc., UroGen Pharma, Inc.

AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

CME Available: https://auau.auanet.org/node/41048

At the conclusion of this activity, participants will be able to:
1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)
2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists.
3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB
4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents
5. Discuss potential future pharmacological pathways and therapies for OAB.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Astellas

Practical Implementation of Third-Line Therapies for Refractory Overactive Bladder (OAB) Webcast (2024)

CME Available: https://auau.auanet.org/node/41056

At the conclusion of this activity, participants will be able to:
1. Discuss the third-line therapies available to treat OAB refractory to conservative techniques.
2. Effectively provide counseling regarding advanced treatment techniques with "friendly, nonthreatening" language that does not intimidate the patients.
3. Consider helpful techniques to optimize lead placement for sacral neuromodulation and be comfortable with troubleshooting the device.
4. Incorporate caveats that are important in the delivery of injections in the bladder for treatment of OAB.
5. Incorporate peripheral nerve stimulation options, including the traditional and newer techniques that will be discuss in detail, into their practice as they see fit.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Astellas

AUA2024: 003IC Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice

CME Available: https://auau.auanet.org/node/40976

At the conclusion of this activity, participants will be able to:
1. Describe key components of genetic risk assessment, genetic counseling and informed consent for genetic testing.
2. Identify elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers and clinical actionability.
3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic result in prostate cancer screening and management of both localized and advanced prostate cancer.
4. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome, and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.